# Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis

> **NCT00291369** · PHASE3 · COMPLETED · sponsor: **Centre Leon Berard** · enrollment: 456 (—)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Interleukin-2
- **DRUG:** Interferon alfa
- **DRUG:** medroxyprogesterone acetate

## Key facts

- **NCT ID:** NCT00291369
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** 456 (—)
- **Last updated:** 2006-02-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00291369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00291369, "Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00291369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*